CLINICAL TRIALS PROFILE FOR LOTEPREDNOL ETABONATE; TOBRAMYCIN
✉ Email this page to a colleague
All Clinical Trials for LOTEPREDNOL ETABONATE; TOBRAMYCIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00420628 ↗ | Pediatric Zylet Safety and Efficacy Study | Completed | Bausch & Lomb Incorporated | Phase 4 | 2006-11-01 | A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum) |
| NCT00447577 ↗ | Zylet vs TobraDex in Blepharokeratoconjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 4 | 2007-01-01 | The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis |
| NCT00834171 ↗ | A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin | Completed | Allergan | 2009-01-01 | Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%) | |
| NCT00905762 ↗ | Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation | Completed | Bausch & Lomb Incorporated | Phase 1 | 2009-03-01 | The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days. |
| NCT01028027 ↗ | Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 3 | 2009-10-01 | This study is to evaluate the safety and efficacy of loteprednol etabonate [LE] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC). |
| NCT03464435 ↗ | A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis | Completed | Zhongshan Ophthalmic Center, Sun Yat-sen University | Phase 4 | 2016-11-01 | To evaluate the efficacy and safety of 0.1% tacrolimus combined with loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) in vernal keratoconjunctivitis (VKC) patients resistant to conventional treatment. This prospective 6-mouth period study aims to include 20 severe VKC patients who were not responding to conventional treatments. All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. Additionally, 0.1% olopatadine two times daily and preservative-free artificial tears four times daily will be used. After the first month, LE/T will be stopped, with other treatments continued for the last 5 months. Visual acuity and intraocular pressure (IOP) will be measured at enrollment and 1, 2, 3 and 6 months after treatment. Besides, 6 subjective symptoms and 6 clinical signs will be graded at each visit based on a 4-point scale. The primary endpoints are the change in symptoms and objective signs. Treatment failure will be recorded if extra corticosteroids were required. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOTEPREDNOL ETABONATE; TOBRAMYCIN
Condition Name
Clinical Trial Locations for LOTEPREDNOL ETABONATE; TOBRAMYCIN
Trials by Country
Clinical Trial Progress for LOTEPREDNOL ETABONATE; TOBRAMYCIN
Clinical Trial Phase
Clinical Trial Sponsors for LOTEPREDNOL ETABONATE; TOBRAMYCIN
Sponsor Name
